Wall Street analysts expect Karyopharm Therapeutics Inc (NASDAQ:KPTI) to report earnings per share (EPS) of ($0.88) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Karyopharm Therapeutics’ earnings, with estimates ranging from ($0.94) to ($0.80). Karyopharm Therapeutics posted earnings per share of ($0.65) in the same quarter last year, which indicates a negative year-over-year growth rate of 35.4%. The company is expected to issue its next earnings report on Thursday, November 1st.
On average, analysts expect that Karyopharm Therapeutics will report full year earnings of ($3.18) per share for the current financial year, with EPS estimates ranging from ($3.36) to ($2.96). For the next fiscal year, analysts anticipate that the business will report earnings of ($3.18) per share, with EPS estimates ranging from ($3.84) to ($2.55). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Karyopharm Therapeutics.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($0.60) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.21. The firm had revenue of $19.89 million for the quarter, compared to analysts’ expectations of $5.97 million.
In other Karyopharm Therapeutics news, major shareholder Ltd Chione sold 50,000 shares of the company’s stock in a transaction on Wednesday, July 18th. The stock was sold at an average price of $18.52, for a total value of $926,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael Kauffman sold 10,000 shares of the company’s stock in a transaction on Wednesday, July 18th. The shares were sold at an average price of $18.27, for a total value of $182,700.00. Following the completion of the sale, the chief executive officer now owns 512,144 shares of the company’s stock, valued at $9,356,870.88. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,056,701 shares of company stock valued at $20,864,276. 13.26% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of the business. Voya Investment Management LLC grew its holdings in Karyopharm Therapeutics by 24.3% in the 2nd quarter. Voya Investment Management LLC now owns 18,661 shares of the company’s stock valued at $317,000 after buying an additional 3,653 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its stake in shares of Karyopharm Therapeutics by 38.9% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock valued at $277,000 after purchasing an additional 4,556 shares during the last quarter. Wells Fargo & Company MN lifted its stake in shares of Karyopharm Therapeutics by 16.3% in the 1st quarter. Wells Fargo & Company MN now owns 36,036 shares of the company’s stock valued at $483,000 after purchasing an additional 5,062 shares during the last quarter. New York State Common Retirement Fund lifted its stake in shares of Karyopharm Therapeutics by 23.6% in the 1st quarter. New York State Common Retirement Fund now owns 37,700 shares of the company’s stock valued at $506,000 after purchasing an additional 7,200 shares during the last quarter. Finally, Swiss National Bank lifted its stake in shares of Karyopharm Therapeutics by 12.8% in the 1st quarter. Swiss National Bank now owns 64,150 shares of the company’s stock valued at $861,000 after purchasing an additional 7,300 shares during the last quarter. Institutional investors own 71.40% of the company’s stock.
Shares of KPTI traded up $0.15 during trading hours on Friday, hitting $12.60. 1,446,974 shares of the stock were exchanged, compared to its average volume of 633,476. Karyopharm Therapeutics has a 12-month low of $9.00 and a 12-month high of $21.71. The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of -4.48 and a beta of 3.75.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Featured Article: What are earnings reports?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.